8-K: Recursion and Exscientia Announce Merger to Forge AI-Powered Drug Discovery Giant

Recursion and Exscientia have agreed to merge, combining their AI-driven drug discovery platforms and pipelines to accelerate the development of new medicines.

Summary

• Recursion and Exscientia have entered into a definitive agreement to combine their businesses, creating a technology-enabled drug discovery company.
• The merger aims to integrate Recursion's biology exploration and translational capabilities with Exscientia's precision chemistry design and automated synthesis.
• The combined company will have a diverse pipeline with approximately 10 clinical readouts expected in the next 18 months.
• The partnership portfolio includes collaborations with major pharmaceutical companies, potentially yielding $200 million in milestone payments over the next 2 years and over $20 billion before royalties.
• The combined entity will have approximately $850 million in cash and is expected to achieve annual synergies of around $100 million, extending the cash runway into 2027.
• Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share, resulting in Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined company.
• The transaction is expected to close by early 2025, subject to shareholder and regulatory approvals.

Sentiment

Score: 9

Explanation: The document is highly positive, emphasizing the strategic benefits of the merger, the potential for significant financial returns, and the advancements in technology and drug discovery. The language is optimistic and forward-looking, suggesting a strong belief in the success of the combined entity.

Positives

• The merger creates a full-stack technology-enabled small molecule discovery platform.
• The combined pipeline is highly complementary, with no competitive overlap.
• The combined company will have a strong financial position with a cash runway into 2027.
• The merger brings together a shared vision to leverage technology for efficient drug discovery.
• The combined company will have a diverse portfolio of transformational partnerships with leading large pharma companies.

Negatives

• The merger is subject to shareholder and regulatory approvals, which could delay or prevent the transaction.
• The integration of two complex businesses may present challenges.
• The realization of the expected synergies and cost savings is not guaranteed.

Risks

• The transaction agreement could be terminated due to various events or circumstances.
• The inability to obtain shareholder or regulatory approvals could prevent the merger.
• The integration of the two companies may disrupt current plans and operations.
• There is a risk of losing key personnel during the integration process.
• The combined company may not be able to realize the expected cost synergies.
• The market value of Recursion's common stock to be issued in the transaction could be affected by various factors.

Future Outlook

The combined company expects to deliver better treatments to patients faster and at a lower cost, leveraging a full-stack technology-enabled platform and a diverse pipeline with approximately 10 clinical readouts expected in the next 18 months. The combined company expects to have a cash runway extending into 2027.

Management Comments

• Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, stated that the merger will bring together complementary capabilities to build the next generation of biotechnology companies.
• David Hallett, Ph.D., Interim CEO of Exscientia, expressed excitement about integrating Recursion's biology capabilities with Exscientia's chemistry and automated synthesis capabilities to accelerate drug discovery.

Industry Context

This merger reflects a growing trend in the pharmaceutical industry towards leveraging AI and technology to improve drug discovery and development efficiency. The combination of Recursion and Exscientia aims to create a leader in this space, potentially setting a new standard for how drugs are discovered and brought to market.

Comparison to Industry Standards

• The document highlights that most of the programs in the combined pipeline, if successful, could have annual peak sales opportunities >$1 billion each, which is a high bar compared to industry averages.
• The document mentions that Recursion's approach enables them to identify low-viability programs earlier in the research cycle, spend less per program, and rapidly advance programs to a validated lead candidate, which is a significant improvement over industry averages.
• The document states that Recursion's automated synthesis capabilities are expected to allow them to more rapidly and effectively run SAR cycles during hit to lead and lead optimization, which is a key differentiator compared to traditional drug discovery methods.
• The document mentions that Recursion's supercomputer, BioHive-2, is ranked 35th most powerful in the world, which is a significant advantage in terms of computational resources compared to most other companies in the industry.

Management Changes

Stakeholder Impact

• Shareholders of both companies are expected to benefit from the combined entity's increased potential for growth and value creation.
• Employees of both companies will have the opportunity to work in a larger, more innovative organization.
• Customers and partners will have access to a broader range of capabilities and resources.
• Patients are expected to benefit from the accelerated development of new medicines.

Next Steps

• The companies will seek shareholder and regulatory approvals for the merger.
• The companies will work to integrate their operations and platforms.
• The combined company will continue to advance its clinical pipeline and partnerships.

Key Dates

Keywords

drug discovery, artificial intelligence, AI, merger, biotechnology, pharmaceutical, clinical trials, partnerships, oncology, rare disease, infectious disease, small molecule, precision chemistry, automated synthesis, milestone payments, synergies